State-of-the-art facility supports advanced cancer treatment applications, accelerating product distribution
Perspective Therapeutics (CATX), a leading radiopharmaceutical company, has announced the first shipment and patient dosing from its second manufacturing facility in Somerset, New Jersey. This state-of-the-art facility is dedicated to the production of the company’s 203Pb- and 212Pb-labeled radiopharmaceuticals, which are used in pioneering cancer treatment applications. The launch marks a significant milestone in Perspective’s mission to provide advanced therapies for cancers throughout the body.
The Somerset facility complements Perspective’s existing manufacturing hub in Coralville, Iowa, which has been producing investigational products for over 15 months. Both sites will now support VMT-α-NET clinical studies and future clinical and commercial demands. With three manufacturing suites designed to meet Current Good Manufacturing Practice (cGMP) standards, the Somerset site is positioned to become a critical part of the company’s production capacity, especially for cancer treatment centers across the Northeastern United States.
The facility was previously operated by Lantheus Holdings, Inc., a leader in the radiopharmaceutical industry, and was used to manufacture Azedra, a radioactive iodine-based treatment approved by the U.S. Food & Drug Administration (FDA) in 2018 for rare adrenal gland tumors. Since its acquisition by Perspective Therapeutics in March 2024, the facility has been retrofitted to produce Perspective’s investigational products.
Shane Cobb, Executive Vice President of Operations at Perspective, expressed his excitement about the rapid development and activation of the new facility. “Going operational seven months after taking possession allows us to accelerate our efforts in delivering investigational products and, pending approval, new radiopharmaceutical therapies,” Cobb noted.
Thijs Spoor, Chief Executive Officer of Perspective, emphasized the importance of this expansion in building the company’s manufacturing and supply chain capabilities. “This new facility reflects our commitment to delivering targeted alpha-particle therapies to patients in critical need. We believe our network approach aligns with patient interests and the half-life profiles of isotopes in our products,” he said. Spoor also indicated plans to replicate this success, with strategic expansions to support key cancer treatment hubs across the U.S.
This expansion strengthens Perspective Therapeutics’ ability to deliver cutting-edge radiopharmaceutical treatments to cancer patients, further positioning the company as a leader in the industry.
You might like this article:AMD’s Growth Outlook: AI Prospects Rise, but Market Challenges Loom
